{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:28:16Z","timestamp":1776065296288,"version":"3.50.1"},"reference-count":42,"publisher":"Portland Press Ltd.","issue":"7","license":[{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>MicroRNAs (miRs) are considered to be tumor suppressors or oncogenes as they regulate cell proliferation, migration, invasion, and differentiation. Recently, microRNA-505 (miR-505) has been reported as being involved in the progression of several human cancers. In the present study, we aim to investigate the expression rate and functional role of miR-505-5p in cervical cancer (CC) to determine its significance regarding the disease\u2019s development.<\/jats:p>\n               <jats:p>The expression of miR-505-5p and cyclin-dependent kinase 5 (CDK5) in specimens of patients with CC and CC cell lines was examined by quantitative real-time PCR (qRT-PCR) and Western Blot. The relationship between miR-505-5p and CDK5 was verified by luciferase reporter assay. Cell counting kit-8 (CCK-8) assay, Scratch wound healing assay and transwell assay were used to detect the roles of miR-505-5p and CDK5 in CC cell functions. Western Blot was utilized to explore the epithelial\u2013mesenchymal transition (EMT) markers.<\/jats:p>\n               <jats:p>The result showed that in CC tissues and CC cell lines miR-505-5p was down-regulated while CDK5 level was up-regulated. MiR-505-5p was closely correlated with the metastasis-associated clinicopathological features. Overexpression of miR-505-5p inhibited cell viability, cell metastasis and EMT in CC cells. CDK5 was confirmed as a direct target of miR-505-5p and inverse relationship between them was also observed. Overexpression of CDK5 reduces the inhibitory effects of miR-505-5p in CC.<\/jats:p>\n               <jats:p>Taken together, these results determine that miR-505-5p is a tumor suppressor miRNA which regulates tumor cell proliferation, migration, and invasion via binding to the functional target CDK5 and demonstrates its potential for future use in the treatment of CC.<\/jats:p>","DOI":"10.1042\/bsr20191221","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T16:05:17Z","timestamp":1562083517000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["MicroRNA-505-5p functions as a tumor suppressor by targeting cyclin-dependent kinase 5 in cervical cancer"],"prefix":"10.1042","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6182-3180","authenticated-orcid":false,"given":"Elena","family":"Kapora","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, China"},{"name":"First department of Gynecology and Obstetrics, Bashkir State Medical University, Ufa, Republic of Bashkortostan 450008, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujun","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indira","family":"Sakhautdinova","sequence":"additional","affiliation":[{"name":"First department of Gynecology and Obstetrics, Bashkir State Medical University, Ufa, Republic of Bashkortostan 450008, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7437-297X","authenticated-orcid":false,"given":"Wenhua","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2019,7,26]]},"reference":[{"key":"2021111619420365500_B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"2021111619420365500_B2","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"2021111619420365500_B3","doi-asserted-by":"publisher","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","article-title":"Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol."},{"key":"2021111619420365500_B4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","article-title":"Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)","volume":"385","author":"Allemani","year":"2015","journal-title":"Lancet"},{"key":"2021111619420365500_B5","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1002\/cncr.30906","article-title":"Cervical cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study","volume":"123","author":"Benard","year":"2017","journal-title":"Cancer"},{"key":"2021111619420365500_B6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"2021111619420365500_B7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs - microRNAs with a role in cancer","volume":"6","author":"Esquela-Kerscher","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"2021111619420365500_B8","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/ijc.29618","article-title":"A systematic study on dysregulated microRNAs in cervical cancer development","volume":"138","author":"He","year":"2016","journal-title":"Int. J. Cancer"},{"key":"2021111619420365500_B9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2217\/fon-2016-0328","article-title":"Deregulated miRNAs in human cervical cancer: functional importance and potential clinical use","volume":"13","author":"Li","year":"2017","journal-title":"Fut. Oncol."},{"key":"2021111619420365500_B10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.gene.2018.06.030","article-title":"Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B\/Wnt\/\u03b2-catenin signaling pathway","volume":"672","author":"Zhang","year":"2018","journal-title":"Gene"},{"key":"2021111619420365500_B11","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.molonc.2015.03.007","article-title":"Comprehensive analysis of microRNA expression profile in malignant glioma tissues","volume":"9","author":"Piwecka","year":"2015","journal-title":"Mol. Oncol."},{"key":"2021111619420365500_B12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.biopha.2018.05.087","article-title":"miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1","volume":"104","author":"Lu","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"2021111619420365500_B13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.20517\/2394-5079.2015.66","article-title":"Identifying microRNA panels specifically associated with hepatocellular carcinoma and its different etiologies","volume":"2","author":"Shen","year":"2016","journal-title":"Hepatoma Res."},{"key":"2021111619420365500_B14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.lfs.2016.05.039","article-title":"MicroRNA-505 suppresses proliferation and invasion in hepatoma cells by directly targeting high-mobility group box 1","volume":"157","author":"Lu","year":"2016","journal-title":"Life Sci."},{"key":"2021111619420365500_B15","doi-asserted-by":"publisher","first-page":"21081","DOI":"10.18632\/oncotarget.15499","article-title":"Epigenetic silencing of miR-520c leads to induced S100A4 expression and its mediated colorectal cancer progression","volume":"8","author":"Mudduluru","year":"2017","journal-title":"Oncotarget"},{"key":"2021111619420365500_B16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4149\/neo_2017_107","article-title":"A microRNA expression signature as a predictor of survival for colon adenocarcinoma","volume":"64","author":"Xu","year":"2017","journal-title":"Neoplasma"},{"key":"2021111619420365500_B17","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1373\/clinchem.2015.238691","article-title":"Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection","volume":"61","author":"Matamala","year":"2015","journal-title":"Clin. Chem."},{"key":"2021111619420365500_B18","first-page":"491","article-title":"MicroRNA-505 is downregulated in human osteosarcoma and regulates cell proliferation, migration and invasion","volume":"39","author":"Liu","year":"2018","journal-title":"Oncol. Rep."},{"key":"2021111619420365500_B19","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1002\/jcb.26445","article-title":"The potential of microRNAs as human prostate cancer biomarkers: a meta-analysis of related studies","volume":"119","author":"Song","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"2021111619420365500_B20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12943-016-0496-4","article-title":"MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-\u03b1","volume":"15","author":"Chen","year":"2016","journal-title":"Mol. Cancer"},{"key":"2021111619420365500_B21","doi-asserted-by":"publisher","first-page":"10437","DOI":"10.1038\/srep10437","article-title":"Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer","volume":"5","author":"Du","year":"2015","journal-title":"Sci. Rep."},{"key":"2021111619420365500_B22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/jama.2013.284664","article-title":"MicroRNA biomarkers in whole blood for detection of pancreatic cancer","volume":"311","author":"Schultz","year":"2014","journal-title":"JAMA"},{"key":"2021111619420365500_B23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.biopha.2017.04.028","article-title":"MicroRNA-505 predicts prognosis and acts as tumor inhibitor in cervical carcinoma with inverse association with FZD4","volume":"92","author":"Ma","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"2021111619420365500_B24","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1158\/0008-5472.CAN-05-3048","article-title":"Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells","volume":"66","author":"Strock","year":"2006","journal-title":"Cancer Res."},{"key":"2021111619420365500_B25","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1158\/0008-5472.CAN-09-1107","article-title":"Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling","volume":"70","author":"Feldmann","year":"2010","journal-title":"Cancer Res."},{"key":"2021111619420365500_B26","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1091\/mbc.e10-12-1010","article-title":"Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5\/p35 pathway","volume":"23","author":"Demelash","year":"2012","journal-title":"Mol. Biol. Cell"},{"key":"2021111619420365500_B27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ccr.2013.08.027","article-title":"The role of Cdk5 in neuroendocrine thyroid cancer","volume":"24","author":"Pozo","year":"2013","journal-title":"Cancer Cell"},{"key":"2021111619420365500_B28","doi-asserted-by":"publisher","first-page":"e2415","DOI":"10.1038\/cddis.2016.333","article-title":"CDK5 functions as a tumor promoter in human colorectal cancer via modulating the ERK5-AP-1 axis","volume":"7","author":"Zhuang","year":"2016","journal-title":"Cell Death Dis."},{"key":"2021111619420365500_B29","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/s41388-017-0103-1","article-title":"Loss of Cdk5 in breast cancer cells promotes ROS-mediated cell death through dysregulation of the mitochondrial permeability transition pore","volume":"37","author":"NavaneethaKrishnan","year":"2018","journal-title":"Oncogene"},{"key":"2021111619420365500_B30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jhep.2015.01.031","article-title":"Targeting cyclin dependent kinase 5 in hepatocellular carcinoma\u2013A novel therapeutic approach","volume":"63","author":"Ehrlich","year":"2015","journal-title":"J. Hepatol."},{"key":"2021111619420365500_B31","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.4161\/cc.21886","article-title":"Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients","volume":"11","author":"Levacque","year":"2012","journal-title":"Cell Cycle"},{"key":"2021111619420365500_B32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12957-015-0629-z","article-title":"Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study","volume":"13","author":"Yushan","year":"2015","journal-title":"World J. Surg. Oncol."},{"key":"2021111619420365500_B33","first-page":"4533","article-title":"Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer","volume":"19","author":"Li","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"2021111619420365500_B34","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1002\/cncr.30667","article-title":"Cervical cancer: A global health crisis","volume":"123","author":"Small","year":"2017","journal-title":"Cancer"},{"key":"2021111619420365500_B35","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.molonc.2012.09.006","article-title":"MicroRNA and cancer","volume":"6","author":"Jansson","year":"2012","journal-title":"Mol. Oncol."},{"key":"2021111619420365500_B36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021111619420365500_B37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3892\/ijmm.2013.1424","article-title":"Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma","volume":"32","author":"Chen","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"2021111619420365500_B38","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12032-015-0510-5","article-title":"Meta-analysis of microRNA expression profiling studies in human cervical cancer","volume":"32","author":"Li","year":"2015","journal-title":"Med. Oncol."},{"key":"2021111619420365500_B39","first-page":"2997","article-title":"Decreased expression of miR-1254 is associated with cancer aggressiveness and predicts poor outcome in cervical cancer","volume":"22","author":"Zhou","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"2021111619420365500_B40","first-page":"623","article-title":"MicroRNA-200c suppressed cervical cancer cell metastasis and growth via targeting MAP4K4","volume":"22","author":"Mei","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"2021111619420365500_B41","first-page":"6393","article-title":"MicroRNA-143 regulates cell migration and invasion by targeting GOLM1 in cervical cancer","volume":"16","author":"Zhou","year":"2018","journal-title":"Oncol. Lett."},{"key":"2021111619420365500_B42","first-page":"5679","article-title":"microRNA-214 suppresses the growth of cervical cancer cells by targeting EZH2","volume":"16","author":"Yang","year":"2018","journal-title":"Oncol. Lett."}],"updated-by":[{"DOI":"10.1042\/bsr-20191221_eoc","type":"expression_of_concern","label":"Expression of concern","source":"retraction-watch","updated":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"record-id":"27500"},{"DOI":"10.1042\/bsr-20191221_ret","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"record-id":"27497"},{"DOI":"10.1042\/bsr-20191221_ret","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000}},{"DOI":"10.1042\/bsr-20191221_eoc","type":"expression_of_concern","label":"Expression of concern","source":"publisher","updated":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000}}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20191221\/846153\/bsr-2019-1221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20191221\/846153\/bsr-2019-1221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:28:36Z","timestamp":1637094516000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/39\/7\/BSR20191221\/219280\/MicroRNA-505-5p-functions-as-a-tumor-suppressor-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20191221","relation":{"retraction":[{"id-type":"doi","id":"10.1042\/BSR-20191221_RET","asserted-by":"object"}],"expression_of_concern":[{"id-type":"doi","id":"10.1042\/BSR-20191221_EOC","asserted-by":"object"}]},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,7]]},"article-number":"BSR20191221"}}